Integrated cardiac safety assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance /
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Searvvušdahkki: | |
| Eará dahkkit: | |
| Materiálatiipa: | Elektrovnnalaš E-girji |
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
Hoboken, N.J. :
John Wiley & Sons,
c2009.
|
| Fáttát: | |
| Liŋkkat: | An electronic book accessible through the World Wide Web; click to view |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Sisdoallologahallan:
- The importance of cardiac safety assessments
- The biological basis of adverse drug reactions
- Cardiac structure and function
- Cardiac pathophysiology and disease
- Drug discovery and drug design
- Nonclinical development
- The thorough QT/QTc trial
- General safety assessments
- Therapeutic use trials and meta-analyses
- Assessment methodologies in nonexperimental postmarketing surveillance
- Postmarketing proarrhythmic cardiac safety assessments
- Generalized cardiac safety
- Medication errors, adherence, and concordance
- Future directions in drug safety.